AU2018209006B2 - Thienopyrimidine derivative and use thereof in medicine - Google Patents

Thienopyrimidine derivative and use thereof in medicine Download PDF

Info

Publication number
AU2018209006B2
AU2018209006B2 AU2018209006A AU2018209006A AU2018209006B2 AU 2018209006 B2 AU2018209006 B2 AU 2018209006B2 AU 2018209006 A AU2018209006 A AU 2018209006A AU 2018209006 A AU2018209006 A AU 2018209006A AU 2018209006 B2 AU2018209006 B2 AU 2018209006B2
Authority
AU
Australia
Prior art keywords
mixture
methyl
mmol
methoxyphenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018209006A
Other languages
English (en)
Other versions
AU2018209006A1 (en
Inventor
Zheng Gu
Chenlu LI
Wanjun TANG
Zhifu WAN
Xiaojun Wang
Xinye YANG
Yingjun Zhang
Zongyuan ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of AU2018209006A1 publication Critical patent/AU2018209006A1/en
Assigned to SUNSHINE LAKE PHARMA CO., LTD. reassignment SUNSHINE LAKE PHARMA CO., LTD. Request for Assignment Assignors: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED, SUNSHINE LAKE PHARMA CO., LTD.
Application granted granted Critical
Publication of AU2018209006B2 publication Critical patent/AU2018209006B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018209006A 2017-01-22 2018-01-22 Thienopyrimidine derivative and use thereof in medicine Active AU2018209006B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017100522753 2017-01-22
CN201710052275 2017-01-22
PCT/CN2018/073581 WO2018133858A1 (en) 2017-01-22 2018-01-22 Thienopyrimidine derivative and use thereof in medicine

Publications (2)

Publication Number Publication Date
AU2018209006A1 AU2018209006A1 (en) 2019-07-25
AU2018209006B2 true AU2018209006B2 (en) 2021-04-22

Family

ID=62908330

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018209006A Active AU2018209006B2 (en) 2017-01-22 2018-01-22 Thienopyrimidine derivative and use thereof in medicine

Country Status (8)

Country Link
US (1) US10759812B2 (enExample)
EP (1) EP3571205B1 (enExample)
JP (1) JP7046959B2 (enExample)
KR (1) KR102577824B1 (enExample)
CN (1) CN108341830B (enExample)
AU (1) AU2018209006B2 (enExample)
CA (1) CA3049816A1 (enExample)
WO (1) WO2018133858A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
CA3137479A1 (en) 2017-03-03 2018-09-07 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
EP3660023B1 (en) * 2017-07-26 2023-03-08 Nanjing Sanhome Pharmaceutical Co., Ltd. Thienopyrimidinedione compounds as acc inhibitors and use thereof
CA3088997A1 (en) 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
CN109810085B (zh) * 2019-04-19 2019-07-19 上海皓元生物医药科技有限公司 Acc抑制剂及其中间体的制备方法
CN111848678A (zh) * 2019-04-30 2020-10-30 正大天晴药业集团股份有限公司 含磷类噻吩并嘧啶衍生物
CN113924303B (zh) * 2019-07-02 2023-10-20 广东东阳光药业股份有限公司 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用
AR119594A1 (es) * 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
US20240002394A1 (en) * 2020-11-24 2024-01-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Deuterium-modified thienopyridone compound
CN116745299A (zh) * 2021-02-07 2023-09-12 正大天晴药业集团股份有限公司 噻吩并嘧啶衍生物
CN117126174B (zh) * 2022-05-26 2025-12-05 广东东阳光药业股份有限公司 噻吩并嘧啶类化合物的共晶及其用途
TW202400151A (zh) * 2022-05-26 2024-01-01 大陸商廣東東陽光藥業股份有限公司 噻吩並嘧啶類化合物的晶型及其用途
CN117126175B (zh) * 2022-05-26 2025-12-05 广东东阳光药业股份有限公司 噻吩并嘧啶类化合物的共晶及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
CA2644996A1 (en) 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
MX370976B (es) * 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
EP2994128B1 (en) 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
WO2015003881A1 (en) 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
MX2017008844A (es) * 2015-01-09 2018-03-14 Gilead Apollo Llc Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
CN108347939B (zh) 2015-11-25 2021-09-28 吉利德阿波罗公司 含有2,4-二氧代-1,4-二氢噻吩并[2,3-d]嘧啶的衍生物的杀真菌组合物
US20170166582A1 (en) 2015-11-25 2017-06-15 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
EP3380478B1 (en) 2015-11-25 2020-12-23 Gilead Apollo, LLC Ester acc inhibitors and uses thereof
WO2017147161A1 (en) 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
CN107698603B (zh) 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN110431144B (zh) 2017-03-24 2022-08-05 浙江海正药业股份有限公司 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途
WO2018171698A1 (zh) 2017-03-24 2018-09-27 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物及其制备方法和用途
WO2018228369A1 (zh) 2017-06-15 2018-12-20 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives

Also Published As

Publication number Publication date
AU2018209006A1 (en) 2019-07-25
JP2020505356A (ja) 2020-02-20
US20190352311A1 (en) 2019-11-21
US10759812B2 (en) 2020-09-01
EP3571205A1 (en) 2019-11-27
JP7046959B2 (ja) 2022-04-04
KR102577824B1 (ko) 2023-09-13
EP3571205A4 (en) 2020-06-03
CN108341830A (zh) 2018-07-31
CA3049816A1 (en) 2018-07-26
CN108341830B (zh) 2021-03-02
KR20190110575A (ko) 2019-09-30
WO2018133858A1 (en) 2018-07-26
EP3571205B1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
US10759812B2 (en) Thienopyrimidine derivative and use thereof in medicine
AU2020214064B2 (en) Hexone glucokinase inhibitor and use thereof
AU2019237992B2 (en) Oxadiazole transient receptor potential channel inhibitors
US11208418B2 (en) Nitrogenous tricyclic compounds and uses thereof in medicine
WO2019034096A1 (en) FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE
JP2019524784A (ja) 窒素含有三環式化合物、および医薬におけるその使用
WO2019076310A1 (en) DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE
CN105399756B (zh) Btk抑制剂及其用途
WO2024057013A1 (en) Nlrp3 modulators
US12428432B2 (en) Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
US20250353855A1 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
HK40011745B (en) Thienopyrimidine derivative and use thereof in medicine
HK40011745A (en) Thienopyrimidine derivative and use thereof in medicine
TW202425971A (zh) 三環類化合物及其製備方法和應用
TW202425972A (zh) 三環類化合物及其製備方法和應用
EP4671242A1 (en) PYRIDOPYRIMIDINE DERIVATIVE AND ITS USES
WO2024061340A1 (en) Nampt modulators, preparations, and uses thereof
EP1864984A1 (en) Tricyclic spiro compound comprising acyl group bound to nitrogen atom in the ring
HK40069535A (en) Thienopyrimidine derivatives having stereo configurations and use thereof in medicine

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SUNSHINE LAKE PHARMA CO., LTD.

Free format text: FORMER APPLICANT(S): NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED; SUNSHINE LAKE PHARMA CO., LTD.

FGA Letters patent sealed or granted (standard patent)